This Plain Language Summary Publication from Future Oncology describes the results from a study called CheckMate 274 which looked at a new medication called nivolumab and how well it worked to reduce the chance of muscle-invasive urothelial cancer returning after surgery.

Read the full article here. 

The original article on which this Plain Language Summary of Publication is based is titled ‘Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma’ and was published in The New England Journal of Medicine. Read the original article here.